

Gibson Dunn Advises Immedica Pharma on Acquisition of Neurocrine Group

Firm News | January 14, 2026

Gibson Dunn is advising Immedica Pharma AB on the acquisition of Neurocrine Group Limited.

Headquartered in Stockholm, Sweden, Immedica focuses on the commercialization of medicines for rare diseases and specialty care products.

Our London team is led by partners Wim De Vlieger and Jakob Egle and includes partner Branden Berns and associates Lucy Carr, Alex Eldredge, and Tracey Tomlinson.

Partner Alison Beal and associates Chris Puttock and Ioana Burtea advised on Privacy/IP/IT matters; partner Karen Spindler and associate Carson Zheng advised on Licensing matters; Partner James Cox and associate Georgia Derbyshire advised on Employment matters; Partner Melissa Farrar and associates Irene Polieri and Victor Tong advised on Anti-Bribery/Anti-Corruption/Sanctions matters; Partner Christian Riis-Madsen and associates Jonas Jousma and Alex Delipallas-O'Donnell advised on Antitrust/Foreign Direct Investment matters; Partners Sandy Bhogal and James Jennings and of counsel Bridget English advised on Tax matters.

Related People

[Wim De Vlieger](#)

[Jakob Egle](#)

[Branden C. Berns](#)

[Lucy Carr](#)

[Alex Eldredge](#)

[Alison Beal](#)

[Georgia Derbyshire](#)

[Melissa L. Farrar](#)

[Irene Polieri](#)

[Victor Tong](#)

[Christian Riis-Madsen](#)

[Jonas L. Jousma](#)

[Alex Delipallas-O'Donnell](#)

[Sandy Bhogal](#)

[James Jennings](#)

[Bridget English](#)

Related Capabilities

[Life Sciences](#)

[Mergers and Acquisitions](#)